Holen Sie sich die Stockscreener-App
42.51
1.75%
0.73
Schlusskurs vom Vortag:
$41.78
Offen:
$42.08
24-Stunden-Volumen:
2.81M
Relative Volume:
1.05
Marktkapitalisierung:
$11.40B
Einnahmen:
$2.17B
Nettoeinkommen (Verlust:
$521.27M
KGV:
24.02
EPS:
1.77
Netto-Cashflow:
$633.79M
1W Leistung:
+2.06%
1M Leistung:
+17.66%
6M Leistung:
-2.77%
1J Leistung:
+22.05%
1-Tages-Spanne:
$41.82
$42.86
1-Wochen-Bereich:
$41.58
$43.16
52-Wochen-Spanne:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Vergleichen Sie EXEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
42.51 | 11.20B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Can Exelixis Inc. (EX9) stock retain market dominanceWeekly Market Report & High Accuracy Investment Signals - newser.com
Why Exelixis Inc. stock attracts high net worth investorsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Will Exelixis Inc. stock sustain high P E ratios2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
How Exelixis Inc. (EX9) stock trades under stagflationDollar Strength & Entry and Exit Point Strategies - newser.com
Exelixis Inc Stock Analysis and ForecastCapital Gains Strategies & Reinvest for Maximum Compounding Returns - earlytimes.in
Using data filters to optimize entry into Exelixis Inc.2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
Can swing trading help recover from Exelixis Inc. lossesPortfolio Value Report & Weekly Hot Stock Watchlists - newser.com
How buyback programs support Exelixis Inc. (EX9) stockWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
Merck and Exelixis reveal their combo study | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Can you recover from losses in Exelixis Inc.Swing Trade & Risk Managed Investment Strategies - newser.com
Can Exelixis Inc. stock deliver consistent earnings growth2025 Momentum Check & High Accuracy Investment Signals - newser.com
Why Exelixis Inc. stock could benefit from AI revolutionPortfolio Growth Summary & Weekly Top Gainers Trade List - newser.com
Will Exelixis Inc. (EX9) stock rise with strong economy2025 Key Highlights & Stepwise Swing Trade Plans - newser.com
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention - sharewise.com
Best data tools to analyze Exelixis Inc. stockJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - newser.com
Former Exelixis GC Named Legal Chief At Cytokinetics - Law360
Trading Systems Reacting to (EXEL) Volatility - news.stocktradersdaily.com
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Key Lessons & Technical Pattern Based Signals - newser.com
How Exelixis Inc. stock trades before earningsJuly 2025 Setups & Consistent Growth Equity Picks - newser.com
This Insider Has Just Sold Shares In Exelixis - 富途牛牛
Real time alert setup for Exelixis Inc. performanceMarket Activity Report & AI Forecast for Swing Trade Picks - newser.com
Why Exelixis Inc. is moving todayOil Prices & Capital Protection Trade Alerts - newser.com
Using RSI to spot recovery in Exelixis Inc.July 2025 Breakouts & Weekly High Potential Stock Alerts - newser.com
Can Exelixis Inc. stock weather global recession2025 Institutional Moves & Accurate Trade Setup Notifications - newser.com
RBC Capital Keeps Their Hold Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis director Papadopoulos sells $4.35 million in stock By Investing.com - Investing.com South Africa
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - sharewise.com
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):